Challenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Michael Sarshad
Advertisement
Director, Commercial Advisory Group, Syneos Health Consulting
Articles by Michael Sarshad
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
Direct-to-patient: pharma’s next power move
3
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
